[Human parathyroid hormone (1-34) as a new therapeutic agent for osteoporosis].
Human parathyroid hormone (PTH) is used clinically for severe osteoporosis in North America and Europe. The clinical trial is now in progress in Japan. In this review, I introduce the additive effects of PTH with bone resorption inhibitors, the different effects on bone structure and quality between PTH and bone resorption inhibitor, and the bone-increasing effects of PTH involved in IGF/IRS, AP-1 and Wnt pathways. I focus on new topics including the presentations in ASBMR (American Society for Bone and Mineral Research) 2004.
Isogai
Yukihiro
Y
1st Laboratory for Pharmacology, Institute for Life Science Research, Asahi Kasei Pharma Co., Ltd., Japan.
D019386:Alendronate / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006801:Humans; D055504:Insulin Receptor Substrate Proteins; D007334:Insulin-Like Growth Factor I / Q000502:physiology; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology; D010012:Osteogenesis / Q000187:drug effects / Q000235:genetics; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology; D010281:Parathyroid Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D010750:Phosphoproteins / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology; D018808:Transcription Factor AP-1 / Q000502:physiology; D051153:Wnt Proteins
C526292:IRS1 protein, human; D055504:Insulin Receptor Substrate Proteins; D036341:Intercellular Signaling Peptides and Proteins; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D010750:Phosphoproteins; D018808:Transcription Factor AP-1; D051153:Wnt Proteins; D007334:Insulin-Like Growth Factor I; D019386:Alendronate